Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of LY3023414 in Japanese Participants With Advanced Cancer
- Conditions
- Neoplasm
- Interventions
- Drug: LY3023414
- First Posted Date
- 2015-09-01
- Last Posted Date
- 2018-07-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 12
- Registration Number
- NCT02536586
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Tokyo, Japan
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
- Conditions
- Advanced CancerMetastatic Cancer
- Interventions
- Drug: LY3076226
- First Posted Date
- 2015-08-20
- Last Posted Date
- 2020-04-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 25
- Registration Number
- NCT02529553
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸The START Center for Cancer Care, San Antonio, Texas, United States
🇨🇦For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Vancouver, British Columbia, Canada
A Study of a New LY900014 Formulation in Healthy Participants
- Conditions
- Healthy
- Interventions
- Drug: LY900014Drug: Insulin Lispro (Humalog)
- First Posted Date
- 2015-08-17
- Last Posted Date
- 2020-05-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 24
- Registration Number
- NCT02525744
- Locations
- 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Singapore, Singapore
A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL
- Conditions
- T-cell Acute Lymphoblastic LeukemiaT-cell Lymphoblastic Lymphoma
- Interventions
- First Posted Date
- 2015-08-07
- Last Posted Date
- 2019-09-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 36
- Registration Number
- NCT02518113
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Texas MD Anderson, Houston, Texas, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers
- First Posted Date
- 2015-08-03
- Last Posted Date
- 2017-05-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 12
- Registration Number
- NCT02514603
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan
A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer
- Conditions
- Gastroesophageal Junction AdenocarcinomaGastric Adenocarcinoma
- Interventions
- First Posted Date
- 2015-08-03
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 245
- Registration Number
- NCT02514551
- Locations
- 🇺🇸
Vista Oncology Inc. PS, Olympia, Washington, United States
🇨🇦For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Oshawa, Canada
🇺🇸Scott & White Memorial Hospital & Clinic, Temple, Texas, United States
A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2015-07-31
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1257
- Registration Number
- NCT02513550
- Locations
- 🇺🇸
David Stoll, M.D., Beverly Hills, California, United States
🇺🇸Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸Dermatology Research Associates, Los Angeles, California, United States
A Study of Different Particle Sizes of Evacetrapib in Healthy Participants
- First Posted Date
- 2015-07-14
- Last Posted Date
- 2018-12-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 95
- Registration Number
- NCT02497391
- Locations
- 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Singapore, Singapore
A Study of Cephalexin Liquid in Healthy Participants
- First Posted Date
- 2015-07-07
- Last Posted Date
- 2016-10-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 28
- Registration Number
- NCT02490670
- Locations
- 🇲🇽
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, Mexico
A Study of Abemaciclib (LY2835219) in Healthy Participants With and Without Food
- First Posted Date
- 2015-06-26
- Last Posted Date
- 2019-01-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 30
- Registration Number
- NCT02482935
- Locations
- 🇺🇸
Covance Clinical Research Unit, Dallas, Texas, United States